

MEDICAL POLICY STATEMENT Arkansas PASSE

Alkalisas PASSE				
Policy Name & Number	Date Effective			
Metabolic Bariatric Surgery AR PASSE-MM-1147	10/01/2022-10/31/2023			
Policy Type				
MEDICAL				

Medical Policy Statement prepared by CareSource and its affiliates are derived from literature based on and supported by clinical guidelines, nationally recognized utilization and technology assessment guidelines, other medical management industry standards, and published MCO clinical policy guidelines. Medically necessary services include, but are not limited to, those health care services or supplies that are proper and necessary for the diagnosis or treatment of disease, illness, or injury and without which the patient can be expected to suffer prolonged, increased or new morbidity, impairment of function, dysfunction of a body organ or part, or significant pain and discomfort. These services meet the standards of good medical practice in the local area, are the lowest cost alternative, and are not provided mainly for the convenience of the member or provider. Medically necessary services also include those services defined in any Evidence of Coverage documents, Medical Policy Statements, Provider Manuals, Member Handbooks, and/or other policies and procedures.

Medical Policy Statements prepared by CareSource and its affiliates do not ensure an authorization or payment of services. Please refer to the plan contract (often referred to as the Evidence of Coverage) for the service(s) referenced in the Medical Policy Statement. If there is a conflict between the Medical Policy Statement and the plan contract (i.e., Evidence of Coverage), then the plan contract (i.e., Evidence of Coverage) will be the controlling document used to make the determination. According to the rules of Mental Health Parity Addiction Equity Act (MHPAEA), coverage for the diagnosis and treatment of a behavioral health disorder will not be subject to any limitations that are less favorable than the limitations that apply to medical conditions as covered under this policy.

Table of Contents

Α.	Subject	2
	Background	
	Definitions	
	Policy	
E.	Conditions of Coverage	4
	Related Policies/Rules	
	Review/Revision History	
	References	



A. Subject

Metabolic and Bariatric Surgery

B. Background

Obesity continues to be a major health threat in the United States affecting an increasingly larger proportion of adults and children. The Centers for Disease Control and Prevention (CDC) estimates that over 41.9% of adults in the United States older than the age of 20 are obese (2017-2020). Obesity in adults aged 40 to 59 is higher (44.3%) than those under aged 40 (39.8%). Statistics indicate that there has been a significant increase in obesity between 1999 through 2020. Obesity-related health problems include hypertension, Type II diabetes, hyperlipidemia, atherosclerosis, heart disease, stroke, diseases of the gallbladder, osteoarthritis, sleep apnea and certain cancers.


The primary goals in achieving optimal health outcomes for Caresource members are providing noninvasive approaches to reduce or prevent obesity by promoting healthy lifestyles that will improve long-term outcomes. For individuals not able to manage severe obesity though non-surgical interventions, metabolic and bariatric surgery options may be an effective intervention.

C. Definitions

- **Body Mass Index (BMI)** An individual's weight in kilograms divided by the square of height in meters.
- Substance Use Disorder (SUD) A cluster of cognitive, behavioral, and physiological symptoms indicating continued use of substances despite significant substance-related problems, encompassing 10 separate classes of drug criteria in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition.
- Behavioral Health Provider A provider of behavioral health services, including a
 psychologist, psychiatrist, and psychiatric nurse practitioner.

D. Policy

- I. Metabolic and bariatric surgery is considered medically necessary when **all** the following criteria are met:
 - A. Primary diagnosis of obesity;
 - B. Member is 13 years of age or older;
 - C. Documentation of a conservative, medically-supervised weight loss program for at least a 6 month period within the last 2 years has been unsuccessful; and
 - D. One of the following BMI requirements are met:
 - 1. BMI ≥40 kg/m²; or
 - 2. BMI ≥35 kg/m² and at least one serious obesity related condition, such as:
 - a. High risk for Type II diabetes (insulin resistance, prediabetes, and/or metabolic syndrome)
 - b. Osteoarthritis of knee or hip
 - c. Improving outcomes of knee or hip replacement
 - d. Obstructive sleep apnea (CPAP should be considered prior to undergoing surgery)
 - e. Non-alcoholic fatty liver disease
 - f. Nonalcoholic steatohepatitis
 - g. Pseudotumor cerebri
 - h. Gastroesophageal reflux disease
 - i. Severe urinary stress incontinence





- j. Poorly controlled hypertension on multiple drug therapy or
- 3. BMI ≥30 kg/m² with Type II diabetes mellitus (DM), if documentation is provided that Type II DM is inadequately controlled despite optimal medical treatment by either oral or injectable medications, including insulin.
- II. Written clinical documentation and supporting information from the attending surgeon must include **all** f the following:
 - 1. Evidence of informed consent.
 - B. Letter from the Primary Care Physician (PCP) or appropriate specialist, including the following content:
 - 1. Medical necessity for procedure;
 - 2. Documentation that member has been evaluated by a nutritionist/dietician during supervised weight loss; and
 - 3. Health-related behaviors, such as smoking history or adherence, have been addressed.
 - C. Evidence that member is participating in a multi-disciplinary program to prepare for surgery and the extended post-operative period.
 - D. Substance use screening results.
 - E. Evidence that harm reduction related to substance use was discussed.
 - F. Evidence that risks of nicotine were discussed.
 - G. Evidence that vitamin B deficiencies were monitored and treated as needed prior to surgery.
 - H. Evidence that member is free of endocrine disease as supported by an endocrine study consisting of a T3, T4, blood sugar and a 17-Keto Steroid or Plasma Cortisol.
 - I. Documentation illustrating the member has been evaluated from a psychological standpoint within the past 6 months by the treating behavioral health provider, including consideration of all of the following:
 - 1. List of co-existing psychiatric conditions;
 - 2. Family and social support;
 - 3. Evidence that the member understands the surgical procedure and can make a responsible decision; and
 - 4. Evidence that the member is stable enough to
 - a. Understand the risks and benefits:
 - b. Change lifestyle through diet moderation and strategic eating;
 - c. Follow through with the extensive aftercare plan;
 - d. Withstand the rigors of surgery; and
 - e. Not show evidence of the likelihood of being suicidal or significantly decompensate if the procedure is not successful in helping to lose weight.
 - J. Complete history and physical, including an assessment, listing of diagnoses, height, weight, BMI, and treatment plan, must be provided. The exclusion or diagnosis of genetic or syndromic obesity, such as Prader-Willi Syndrome, must also be documented.
 - K. For women with reproductive capacity, appropriate conception counseling was discussed and documented, including the following:
 - 1. Clear documentation that supports that the member has agreed to avoid pregnancy for at least one year postoperatively.

Metabolic Bariatric Surgery AR PASSE-MM-1147 Effective Date: 10/01/2022



a. Discussion includes potential birth defects from nutritional deficiencies that can occur if she does become pregnant during the weight stabilization period following surgery.

- III. Contraindications/Noncovered procedures
 - A. Surgery is contraindicated in the following:
 - 1. A medically correctable cause of obesity;
 - 2. Current or planned pregnancy within one year of procedure;
 - 3. Active suicidality or self-harm;
 - 4. Active psychosis;
 - 5. Active substance use disorder;
 - 6. Ongoing substance abuse disorder within the previous year;
 - 7. Severe coagulopathy;
 - 8. Uncontrolled and untreated eating disorders; and
 - 9. Inability to comply with postoperative long-term follow-up care.
 - B. The intended procedure is not covered if it is experimental or investigational. These include, but are not limited to:
 - 1. Endoscopic bariatric and metabolic therapies, such as Intragastric balloon (IGR):
 - 2. Endoscopic sleeve gastroplasty (ESG) and
 - 3. Aspiration therapy (AT)
- IV. The following members should be referred to an accredited comprehensive center
 - A. BMI >55kg/m²
 - B. Members with the following issues:
 - 1. Organ failure;
 - 2. Organ transplant;
 - 3. Significant cardiac or pulmonary impairment;
 - 5. On a transplant list; or
 - 6. Non-ambulatory.
- E. Conditions of Coverage

NA

F. Related Policies/Rules
Metabolic and Bariatric Surgery: Revision

G. Review/Revision History


DA	ATES	ACTION
Date Issued	01/06/2021	
Date Revised	06/22/2022	Updated references. Updated demographic information in background. Removed documentation requirement from III. J. that member was not currently pregnant. Added E&I devices to IV. B.



		Removed "Adults age18-65" from title. Sec. I. B. stated "B. Member is 13 years of age or older." Added MCG to references.
Date Effective	10/01/2022	
Date Archived	10/31/2023	This Policy is no longer active and has been archived. Please note that there could be other Policies that may have some of the same rules incorporated and CareSource reserves the right to follow CMS/State/NCCI guidelines without a formal documented Policy.

H. References

- 1. American Diabetes Association. (2020, January). Obesity management for the Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes 2020. Diabetes Care. 43(1). https://doi.org/10.2337/dc20-S008.
- 2. American Society for Metabolic and Bariatric Surgery. The Impact of Obesity on Your Body and Health. (n.d.). Retrieved December 14, 2020 from www.asmbs.org.
- 3. Centers for Disease Control and Prevention. (2021). Prevalence of Childhood Obesity in the United States, Retrieved on July 12, 2022 from www.cdc.gov.
- 4. Centers for Disease Control and Prevention. (2021). Prevalence of Obesity and Severe Obesity Among Adults: United States, 2017-2020. Retrieved July 12, 2022 from www.cdc.gov.
- 5. Federal Drug Administration. (2020, April 27). *Weight-Loss and Weight-Management Devices*. Retrieved June 6, 2022 from www.fda.gov.
- 6. Kalarchian, M. (2007). Psychiatric Disorders Among Bariatric Surgery Candidates: Relationship to Obesity and Functional Health Status. American Journal of Psychiatry, 164(2), 328. doi:10.1176/appi.aip.164.2.328.
- 7. Lorenzo, N, Antonious S,& Silecchia, G. Clinical practice guidelines of the European Association for Endoscopic Surgery (EAES) on bariatric surgery: update 2020 endorsed by IFSO-EC, EASO and ESPCOP. Surgical endoscopy. 34(6). DOI: 10.1007/s00464-020-07555-y.
- 8. Marcus, M. D., Kalarchian, M. A., & Courcoulas, A. P. (2009). Psychiatric evaluation and follow-up of Bariatric surgery patients. American Journal of Psychiatry, 166(3), 285–291. doi:10.1176/appi.ajp.2008.08091327.
- 9. MCG Guidelines. 26th ed. Gastric Restrictive Procedure with Gastric Bypass (S-512). July 12, 2022 from www.careweb.careguidelines.com.
- Mechanisk, J, et al. (December 2019). AACE/TOS/ASMBS/OMA/ASA 2019
 Guidelines. Clinical practice Guidelines for the Perioperative Nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures 2019 Update:
 Cosponsored by American Association of Clinical Endocrinologist/American college of Endocrinology, The obesity society, American Society for metabolic & Bariatric surgery, Obesity medicine Association, and American Society of Anesthesiologists.
 Endocrine Practice. 25(12). DOI: 10.4158/ GL-2019-0406.
- 11. National institute of Diabetes and Digestive and Kidney Disease. (n.d.). Retrieved July 12, 2022, from www.niddk.nih.gov.
- 12. Obesity Management for the Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes 2019, American Diabetes Association, Diabetes Care 2019 Jan; 42(Supplement 1): S81-S89 www.care.diabetesjournals.org.
- 13. The Practical Guide to Identification and Treatment of Overweight and Obesity in Adults. (2000, October). Retrieved July 12, 2022 from www.nhlbi.nih.gov.



Effective Date: 10/01/2022

Care Source

14. Shekelle, P. G. (2014, October). Mental Health Assessment and Psychological

Care Source

Retrieved July 12, 2022 from www.hsrd.research.va.gov.

15. Yung-Chieh, Y, Huang, C, Tai, C. (2014, September). Current Opinion in Psychiatry. 27(5). doi: 10.1097/YCO.000000000000085.

